Baldo et al. [28] summarized current treatment in MAS worldwide, demonstrating that high-dose glucocorticosteroids with IL-1 or IFN-γ inhibitors are good therapeutic options, especially in systemic juvenile idiopathic arthritis-associated MAS. Here, IFNG is linked to macrophage activation syndrome.